Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23514623 | 0.86 | MAOB (0.58) | MAPTRAB9ACA1CA2CHRNB2 | |
| SCHEMBL8727410 | 0.84 | MAPT (0.68) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL11746611 | 0.84 | CA12 (0.59) | MAPTCA1CA2NPC1CHRNB2 | |
| SCHEMBL4592147 | 0.83 | CA12 (0.54) | MAPTCA1CA2CHRNB2CHRNB4 | |
| SCHEMBL106443 | 0.83 | MAOA (0.48) | MAPTCA1CA2CHRNB2CHRNB4 | |
| SCHEMBL4279603 | 0.83 | MAOA (0.48) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL1249230 | 0.83 | MAPT (0.66) | MAPTRAB9ACA1CA2SMN1; SMN2 | |
| SCHEMBL9155792 | 0.82 | L3MBTL1 (0.61) | MAPTRAB9ACA1CA2CHRNB2 | |
| SCHEMBL28566032 | 0.82 | KMT2A (0.52) | MAPTRAB9ACA1CA2NPC1 | |
| SCHEMBL11957497 | 0.82 | CA12 (0.53) | MAPTRAB9ACA1CA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086633-A1 | RNAI AGENTS FOR INHIBITING EXPRESSION OF DM1 PROTEIN KINASE (DMPK) COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| CN-114746411-A | Substituted tricyclic compounds | 印度鲁宾有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| WO-2022056273-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| US-9968092-B2 | Combination of novel nitrification inhibitors and biopesticides as well as combination of (thio)phosphoric acid triamides and biopesticides | BASF SE (DE) | 2018-05-15 | — | — | US | disclosed |
| US-9968092-B2 | Combination of novel nitrification inhibitors and biopesticides as well as combination of (thio)phosphoric acid triamides and biopesticides | BASF SE (DE) | 2018-05-15 | — | — | US | disclosed |
| WO-2012031298-A2 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| WO-2010031750-A1 | ORGANIC COMPOUNDS FOR APPLICATIONS IN BACTERIAL INFECTIONS TREATMENT | NOVARTIS AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2009-03-26 | — | — | US | disclosed |
| EP-1986694-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | Novo Nordisk A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093594-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (DK) | 2007-08-23 | — | — | WO | disclosed |
| US-5475133-A | Acetylenic monomers containing phenyl, ester and ether groups, for composites, prepregs, curable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082254-A1 | Coupling of Polypeptides at the C-Terminus | PTMS, VIP, LNPEP | MAPT 3874/4885RAB9A 3690/4885CA1 2877/4885 |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | NMT2, NAPRT, NAMPT | MAPT 1437/4885RAB9A 4617/4885CA1 782/4885 |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | MAPT 3973/4885RAB9A 1179/4885CA1 4853/4885 |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | MAPT 1444/4885RAB9A 4474/4885CA1 2516/4885 |
| US-20230265430-A1 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | ZFX, DDX39B, DDX21 | MAPT 3903/4885RAB9A 1134/4885CA1 4763/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | MAPT 4094/4885RAB9A 977/4885CA1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.